摘要
人3型副流感病毒(Human Parainfluenza Virus type 3,HPIV-3)是引起婴幼儿严重细支气管炎及肺炎等下呼吸道疾病的主要病原体,其在发达国家和发展中国家都造成了沉重的疾病负担。迄今,对HPIV-3感染的预防和治疗都还没有有效的疫苗和药物,因此WHO将HPIV-3疫苗列为未来重点研发的疫苗。近年来,随着重组技术和反向遗传学的发展,HPIV-3疫苗的研制取得了重要进展,部分疫苗已进入临床评价阶段。就HPIV-3的生物学特性如病毒结构特征、复制过程、流行病学特征,以及近年来传统冷适应减毒活疫苗、亚单位疫苗、以反向遗传学为基础的新型减毒活疫苗的研制成果及临床试验进展作简要综述。
Human parainfluenza virus type 3（ HPIV-3） as a cause of bronchiolitis and pneumonia in children less than 6months old,and resulting a heavy burden of disease in developing countries as well as in developed countries. In recent years of research,especially with the development of recombinant technology and reverse genetics,many important progresses have been made in the development of HPIV-3 vaccines but there is still no effective antiviral therapy and licensed vaccine exist for HPIV-3 infection,therefore,WHO has listed HPIV-3 vaccine as the priority development of vaccines in the future. In this paper,the biological characteristics,such as virus structural features,the replication process,and the epidemiological characteristics of HPIV-3 and recent development of various forms of HPIV-3 vaccines and progress in clinical trials for HPIV-3 vaccines are reviewed.
出处
《微生物学免疫学进展》
2015年第4期61-68,共8页
Progress In Microbiology and Immunology
